Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13702321 | 0.82 | L3MBTL1 (0.72) | L3MBTL1HSD11B1EPHX2HSD17B10ALDH1A1 | |
| SCHEMBL12968364 | 0.82 | L3MBTL1 (0.72) | L3MBTL1HSD11B1EPHX2HSD17B10ALDH1A1 | |
| SCHEMBL1923226 | 0.82 | L3MBTL1 (0.61) | L3MBTL1HSD11B1EPHX2HSD17B10ALDH1A1 | |
| SCHEMBL1402737 | 0.81 | L3MBTL1 (0.66) | L3MBTL1HSD11B1EPHX2HSD17B10ALDH1A1 | |
| SCHEMBL15224285 | 0.80 | L3MBTL1 (0.59) | L3MBTL1HSD11B1EPHX2HSD17B10ALDH1A1 | |
| SCHEMBL1402900 | 0.79 | L3MBTL1 (0.59) | L3MBTL1HSD11B1EPHX2HSD17B10ALDH1A1 | |
| SCHEMBL618834 | 0.79 | L3MBTL1 (0.59) | L3MBTL1HSD11B1EPHX2HSD17B10ALDH1A1 | |
| SCHEMBL19808153 | 0.79 | L3MBTL1 (0.63) | L3MBTL1HSD11B1EPHX2HSD17B10ALDH1A1 | |
| SCHEMBL1223956 | 0.79 | L3MBTL1 (0.57) | L3MBTL1HSD11B1EPHX2HSD17B10EPHX1 | |
| SCHEMBL12344537 | 0.78 | L3MBTL1 (1.00) | L3MBTL1HSD11B1EPHX2HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570157-B2 | Cyclic diarylboron derivatives as NLRP3 inflammasome inhibitors | THE UNIVERSITY OF MANCHESTER (GB) | 2020-02-25 | — | — | US | disclosed |
| US-20180215772-A1 | CYCLIC DIARYLBORON DERIVATIVES AS NLRP3 INFLAMMASOME INHIBITORS | THE UNIVERSITY OF MANCHESTER (GB) | 2018-08-02 | — | — | US | disclosed |
| US-8344016-B2 | Pyrazole derivatives as 11-beta-HSD1 inhibitors | ASTRAZENECA AB (SE) | 2013-01-01 | — | — | US | disclosed |
| US-8344016-B2 | Pyrazole derivatives as 11-beta-HSD1 inhibitors | ASTRAZENECA AB (SE) | 2013-01-01 | — | — | US | disclosed |
| US-8344016-B2 | Pyrazole derivatives as 11-beta-HSD1 inhibitors | ASTRAZENECA AB (SE) | 2013-01-01 | — | — | US | disclosed |
| US-20110224273-A1 | Pyrazole Derivatives as 11-Beta-HSD1 Inhibitors | ASTRAZENECA AB (SE) | 2011-09-15 | — | — | US | disclosed |
| US-20110224273-A1 | Pyrazole Derivatives as 11-Beta-HSD1 Inhibitors | ASTRAZENECA AB (SE) | 2011-09-15 | — | — | US | disclosed |
| US-20110224273-A1 | Pyrazole Derivatives as 11-Beta-HSD1 Inhibitors | ASTRAZENECA AB (SE) | 2011-09-15 | — | — | US | disclosed |
| EP-2292228-A1 | Pyrazole derivatives as 11-beta-HSD1 inhibitors | AstraZeneca AB (Publ) (SE) | 2011-03-09 | — | — | EP | disclosed |
| EP-2292228-A1 | Pyrazole derivatives as 11-beta-HSD1 inhibitors | AstraZeneca AB (Publ) (SE) | 2011-03-09 | — | — | EP | disclosed |
| EP-2271629-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | AstraZeneca AB (SE) | 2011-01-12 | — | — | EP | disclosed |
| US-7816391-B2 | 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid; hydroxysteroid reductase inhibitors; hydrolysis; metabolic syndromes | ASTRAZENECA AB (SE) | 2010-10-19 | — | — | US | disclosed |
| US-7816391-B2 | 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid; hydroxysteroid reductase inhibitors; hydrolysis; metabolic syndromes | ASTRAZENECA AB (SE) | 2010-10-19 | — | — | US | disclosed |
| WO-2009130496-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | WO | disclosed |
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
| US-20090221663-A1 | PYRAZOLE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090221663-A1 | PYRAZOLE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| WO-2008099145-A1 | PYRAZOLE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | CYP2S1, HSD11B1, HSD3B1 | L3MBTL1 4728/4885HSD11B1 2/4885EPHX2 756/4885 |
| US-20110224273-A1 | Pyrazole Derivatives as 11-Beta-HSD1 Inhibitors | HSD11B1, HSD3B1, HSD11B2 | L3MBTL1 4595/4885HSD11B1 1/4885EPHX2 1955/4885 |
| US-10570157-B2 | Cyclic diarylboron derivatives as NLRP3 inflammasome inhibitors | NLRP3, IL1B, NOD1 | L3MBTL1 2020/4885HSD11B1 270/4885EPHX2 2771/4885 |
| US-20180215772-A1 | CYCLIC DIARYLBORON DERIVATIVES AS NLRP3 INFLAMMASOME INHIBITORS | NLRP3, IL1B, NOD1 | L3MBTL1 2020/4885HSD11B1 270/4885EPHX2 2771/4885 |
| US-20090221663-A1 | PYRAZOLE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | HSD11B1, HSD3B1, HSD11B2 | L3MBTL1 4595/4885HSD11B1 1/4885EPHX2 1955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.